$Genmab (GMAB.US)$
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

$Genmab (GMAB.US)$ can it touch 24? or it will drop more? since opens low today🙄

$Genmab (GMAB.US)$
Breakthrough Lymphoma Drug EPKINLY Scores Dual Approval in Japan: 95% Patient Response

$Genmab (GMAB.US)$ growth up positive trend

$Genmab (GMAB.US)$ positive growth $26, growth upwards trend

$Genmab (GMAB.US)$ growth is very slow

$Genmab (GMAB.US)$ $AbbVie (ABBV.US)$
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)

🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co (MRK.US)$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma (VRNA.US)$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab (GMAB.US)$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co (MRK.US)$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...

Pre-Market Stock Movers
Gapping up
$NVIDIA (NVDA.US)$
(The chipmaker popped 7% after reporting another blowout quarter that topped Wall Street’s estimates. Nvidia also offered optimistic guidance, saying that sales will jump 170% during the current period as demand for AI chips continues to gain steam. Adjusted earnings came in at $2.70 per share, ahead of the $2.09 estimate expected from analysts polled by Refinitiv. Nv...